ECCO 2023
JAK inhibitors - small molecules to treat IBD
© 2021 onkowissen.de GmbH.
All rights reserved.
90 Videos online
Supported by
high5immunology.tv | IBD | ECCO 2023
ECCO 2023
S. Danese, F. Magro, I. Dotan, S. Schreiber, A. Dignaß, A. Moschen, S. Vermeire, P. Irving
JAK inhibitors - small molecules to treat IBD
U-EXCEL, U-EXCEED, U-ENDURE
ECCO 2023
S. Danese, F. Magro, I. Dotan, S. Schreiber, A. Dignaß, A. Moschen, S. Vermeire, P. Irving
S1P modulators - a rising class of drugs
ELEVATE, True North OLE
ECCO 2023
S. Danese, F. Magro, I. Dotan, S. Schreiber, A. Dignaß, A. Moschen, S. Vermeire, P. Irving
New molecules on the horizon!
APOLLO-CD, ARTEMIS-UC
ECCO 2023
S. Danese, F. Magro, I. Dotan, S. Schreiber, A. Dignaß, A. Moschen, S. Vermeire, P. Irving
A focus on surgery and post-operative maintenance
LIR!C, REPREVIO
S. Danese, F. Magro, I. Dotan, S. Schreiber, A. Dignaß, A. Moschen, S. Vermeire, P. Irving
ECCO 2023
JAK inhibitors - small molecules to treat IBD
S. Danese, F. Magro, I. Dotan, S. Schreiber, A. Dignaß, A. Moschen, S. Vermeire, P. Irving
ECCO 2023
S1P modulators - a rising class of drugs
S. Danese, F. Magro, I. Dotan, S. Schreiber, A. Dignaß, A. Moschen, S. Vermeire, P. Irving
ECCO 2023
New molecules on the horizon!
S. Danese, F. Magro, I. Dotan, S. Schreiber, A. Dignaß, A. Moschen, S. Vermeire, P. Irving
ECCO 2023
A focus on surgery and post-operative maintenance
ECCO 2023
Massimo Claudio Fantini, MD
Prolonged treatment with Ozanimod recaptures remission...
True North OLE
ECCO 2023
Séverine Vermeire, MD
Upadacitinib is efficacious for UC regardless of...
U-ACHIEVE, U-ACCOMPLISH
ECCO 2023
James Lindsay, MD
Upadacitinib works in bionaive and bio-exposed pts in...
U-EXCEL, U-EXCEED, U-ENDURE U-ACHIEVE, U-ACCOMPLISH
ECCO 2023
Gerhard Rogler, MD
No impact of previous therapies for Upadacitinib in...
U-EXCEL, U-EXCEED, U-ENDURE
ECCO 2023
Fernando Magro, MD
Mucosal healing induced by vedolizumab in chronic...
EARNEST
ECCO 2023
Peter Irving, MD
Upadacitinib for fistulizing Crohn´s disease?
U-ENDURE, U-EXCEED, U-EXCEL
ECCO 2023
Séverine Vermeire, MD
Long-term duration of response with ozanimod in UC
True North OLE
Massimo Claudio Fantini, MD
ECCO 2023
Prolonged treatment with Ozanimod recaptures remission in about 1/3 of UC patients not responding at week 10
Séverine Vermeire, MD
ECCO 2023
Upadacitinib is efficacious for UC regardless of biologic pretreatment
Axel Dignaß, MD
ECCO 2023
S1P modulators in UC
James Lindsay, MD
ECCO 2023
Upadacitinib works in bionaive and bio-exposed pts in CD and UC
Gerhard Rogler, MD
ECCO 2023
No impact of previous therapies for Upadacitinib in Crohn's disease
Fernando Magro, MD
ECCO 2023
Mucosal healing induced by vedolizumab in chronic pouchitis
Gerassimos Mantzaris, MD
ECCO 2023
Medium-term outcome of IBD patients diagnosed at preclinical stage
ECCO 2023
Massimo Claudio Fantini, MD
Il prolungamento del trattamento con Ozanimod induce...
True North OLE
ECCO 2023
Séverine Vermeire, MD
Lang Termijn respons met ozanimod bij colitis ulcerosa
True North OLE
ECCO 2023
Séverine Vermeire, MD
Upadacitinib is efficient bij colitis ulcerosa,...
U-ACHIEVE, U-ACCOMPLISH
ECCO 2023
Axel Dignaß, MD
S1P-Modulatoren bei Colitis ulcerosa
True North, True North OLE, ELEVATE
ECCO 2023
Gerhard Rogler, MD
Upadacitinib: Vortherapien spielen keine Rolle mehr bei...
U-EXCEL, U-EXCEED, U-ENDURE
Gerassimos Mantzaris, MD
ECCO 2023
Η μεσοπρόθεσμη έκβαση ασθενών με ΙΦΝΕ που διαγιγνώσκονται σε προκλινικό στάδιο
Massimo Claudio Fantini, MD
ECCO 2023
Il prolungamento del trattamento con Ozanimod induce remissione clinica in circa 1/3 dei pazienti trattati e che non hanno mostrato risposta clinica entro le prime 10 settimane
Séverine Vermeire, MD
ECCO 2023
Lang Termijn respons met ozanimod bij colitis ulcerosa
Séverine Vermeire, MD
ECCO 2023
Upadacitinib is efficient bij colitis ulcerosa, ongeacht eerdere blootstelling aan biologische therapieen
Axel Dignaß, MD
ECCO 2023
S1P-Modulatoren bei Colitis ulcerosa
Gerhard Rogler, MD
ECCO 2023
Upadacitinib: Vortherapien spielen keine Rolle mehr bei Morbus Crohn
ECCO 2023
M. C. Fantini, M. Allez, A. Armuzzi, F. Gomollón, G. Mantzaris, A. Dignass, S. Schreiber
Anti-IL23 drugs: is it all the same?
ADVANCE, MOTIVATE, FORTIFY, GETAID, LUCENT-1 & -2
ECCO 2023
M. C. Fantini, M. Allez, A. Armuzzi, F. Gomollón, G. Mantzaris, A. Dignass, S. Schreiber
New aspects on safety of anti-TNF treatment
GETAID
ECCO 2023
M. C. Fantini, M. Allez, A. Armuzzi, F. Gomollón, G. Mantzaris, A. Dignass, S. Schreiber
Safety update on JAKis - new worries?
U-ACHIEVE, U-ACCOMPLISH, FINCH
ECCO 2023
M. C. Fantini, M. Allez, A. Armuzzi, F. Gomollón, G. Mantzaris, A. Dignass, S. Schreiber
S1P-modulators: a spotlight on safety
True North OLE, ELEVATE
M. C. Fantini, M. Allez, A. Armuzzi, F. Gomollón, G. Mantzaris, A. Dignass, S. Schreiber
ECCO 2023
Anti-IL23 drugs: is it all the same?
M. C. Fantini, M. Allez, A. Armuzzi, F. Gomollón, G. Mantzaris, A. Dignass, S. Schreiber
ECCO 2023
New aspects on safety of anti-TNF treatment
M. C. Fantini, M. Allez, A. Armuzzi, F. Gomollón, G. Mantzaris, A. Dignass, S. Schreiber
ECCO 2023
Safety update on JAKis - new worries?
M. C. Fantini, M. Allez, A. Armuzzi, F. Gomollón, G. Mantzaris, A. Dignass, S. Schreiber
ECCO 2023
S1P-modulators: a spotlight on safety
ECCO 2023
Massimo Claudio Fantini, MD
Etrasimod shows fast stool frequency and rectal...
ELEVATE
ECCO 2023
Gerassimos Mantzaris, MD
Positive effects of Upadacitinib on resolution of...
U-ACHIEVE, U-ACCOMPLISH
ECCO 2023
Massimo Claudio Fantini, MD
Ozanimod shows good efficacy and safety profile in UC...
True North OLE
Massimo Claudio Fantini, MD
ECCO 2023
Etrasimod shows fast stool frequency and rectal bleeding normalization in UC patients
Gerassimos Mantzaris, MD
ECCO 2023
Positive effects of Upadacitinib on resolution of abdominal symptoms and normalization of fatigue in active UC pts
Massimo Claudio Fantini, MD
ECCO 2023
Ozanimod shows good efficacy and safety profile in UC patients after 2 and 3 years of treatment
ECCO 2023
Massimo Claudio Fantini, MD
Rapido controllo del sanguinamento rettale e della...
ELEVATE
ECCO 2023
Gerassimos Mantzaris, MD
Το upadacitinib επιφέρει ύφεση των κοιλιακών...
U-ACHIEVE, U-ACCOMPLISH
ECCO 2023
Massimo Claudio Fantini, MD
Ozanimod shows good efficacy and safety profile after...
True North OLE
Massimo Claudio Fantini, MD
ECCO 2023
Rapido controllo del sanguinamento rettale e della frequenza evacuativa in pazienti affetti da RCU trattati con Etrasimod
Gerassimos Mantzaris, MD
ECCO 2023
Το upadacitinib επιφέρει ύφεση των κοιλιακών συμπτωμάτων και αποκατάσταση της χρόνιας κόπωσης σε ασθενείς με ενεργό ελκώδη κολίτιδα
Massimo Claudio Fantini, MD
ECCO 2023
Ozanimod shows good efficacy and safety profile after 2&3 years of treatment
David Laharie, MD
ECCO 2023
Les antibiotiques dans la petite enfance augmentent le risque de maladie de Crohn pédiatrique
ECCO 2023
J. Lindsay, D. Laharie, P. Eder, G. Rogler, A. Dignaß, S. Schreiber
10 years of Tofacitinib – still more lessons to learn
ECCO 2023
J. Lindsay, D. Laharie, P. Eder, G. Rogler, A. Dignaß, S. Schreiber
Practice-changing data on surgery in CD and UC
REPREVIO, EpiPSC2
J. Lindsay, D. Laharie, P. Eder, G. Rogler, A. Dignaß, S. Schreiber
ECCO 2023
10 years of Tofacitinib – still more lessons to learn
J. Lindsay, D. Laharie, P. Eder, G. Rogler, A. Dignaß, S. Schreiber
ECCO 2023
Practice-changing data on surgery in CD and UC
ECCO 2023
Alexander Moschen, MD
Epigenetic fingerprinting - a novel tool for precision...
EPIC-CD
ECCO 2023
James Lindsay, MD
DNA methylation predicts response to biologics in IBD
EPIC-CD
ECCO 2023
David Laharie, MD
Vedolizumab for preventing postoperative reccurence of...
REPREVIO
ECCO 2023
Gerassimos Mantzaris, MD
Is it feasible to stop anti-TNF treatment in...
GETECCU (EXIT)
Alexander Moschen, MD
ECCO 2023
Epigenetic fingerprinting - a novel tool for precision medicine in IBD
David Laharie, MD
ECCO 2023
Vedolizumab for preventing postoperative reccurence of CD
Gerassimos Mantzaris, MD
ECCO 2023
Is it feasible to stop anti-TNF treatment in combinational therapies in IBD?
Piotr Eder, MD
ECCO 2023
Ileocaecal Crohn's disease - should we call the surgeon first?
Stefan Schreiber, MD
ECCO 2023
New drugs on the block!
Séverine Vermeire, MD
ECCO 2023
Surgical and post-operative management in CD
Matthieu Allez, MD
ECCO 2023
Surgery in CD - resetting or not?
ECCO 2023
Gerassimos Mantzaris, MD
Είναι ευχερές να διακόψουμε τους αντι-TNF παράγοντες...
GETECCU (EXIT)
ECCO 2023
Silvio Danese, MD
Vedolizumab previene la recidiva post operatoria nei...
REPREVIO
ECCO 2023
Matthieu Allez, MD
Résection chirurgicale au course de la maladie de...
REPREVIO, LIR!C
ECCO 2023
David Laharie, MD
Vedolizumab en prévention de la récidive postopératoire...
REPREVIO
ECCO 2023
Alexander Moschen, MD
Epigenetic Fingerprinting - ein neues Werkzeug für die...
EPIC-CD
Gerassimos Mantzaris, MD
ECCO 2023
Είναι ευχερές να διακόψουμε τους αντι-TNF παράγοντες από τη συνδυασμένη θεραπείας τους με κλασικά ανοσοκατασταλτικά
Piotr Eder, MD
ECCO 2023
Postać ileocekalna choroby Crohna - czy chirurgia ma pierwszeństwo?
Séverine Vermeire, MD
ECCO 2023
Aanpak van de (post)operatieve Crohn patient
Silvio Danese, MD
ECCO 2023
Vedolizumab previene la recidiva post operatoria nei pazienti con malattia di Crohn
Stefan Schreiber, MD
ECCO 2023
Biosimilars
Matthieu Allez, MD
ECCO 2023
Résection chirurgicale au course de la maladie de Crohn: une remise a zéro ou pas?
David Laharie, MD
ECCO 2023
Vedolizumab en prévention de la récidive postopératoire de la MC
Alexander Moschen, MD
ECCO 2023
Epigenetic Fingerprinting - ein neues Werkzeug für die Präzisionsmedizin bei CED
David Laharie, MD
ECCO 2023
Résection chirurgicale précoce dans la MC
ECCO 2023
J. Lindsay, D. Laharie, P. Eder, G. Rogler, A. Dignaß, S. Schreiber
Comprehensive remission - the new standard!?
IBD-BOOST survey, LUCENT-1, LUCENT-2
ECCO 2023
J. Lindsay, D. Laharie, P. Eder, G. Rogler, A. Dignaß, S. Schreiber
Histology - a new therapeutic target in UC?
EARNEST
J. Lindsay, D. Laharie, P. Eder, G. Rogler, A. Dignaß, S. Schreiber
ECCO 2023
Comprehensive remission - the new standard!?
J. Lindsay, D. Laharie, P. Eder, G. Rogler, A. Dignaß, S. Schreiber
ECCO 2023
Histology - a new therapeutic target in UC?
Stefan Schreiber, MD
ECCO 2023
Comprehensive Disease Control
Stefan Schreiber, MD
ECCO 2023
Comprehensive Disease Control
ECCO 2023
Piotr Eder, MD
New ECCO guidelines on extraintestinal manifestations...
ECCO guideline
ECCO 2023
Massimo Claudio Fantini, MD
New opportunities from the application of artificial...
Alexander Moschen, MD
ECCO 2023
GPX4 fueling postoperative recurrence in Crohn's disease
Iris Dotan, MD
ECCO 2023
Mucosal signatures suggest a mechanism for early CD postoperative recurrence
Fernando Gomollón, MD
ECCO 2023
Our patients will be better off in the near future!
Alessandro Armuzzi, MD
ECCO 2023
Sequencing in IBD - congress overview
Piotr Eder, MD
ECCO 2023
New ECCO guidelines on extraintestinal manifestations in IBD
Alessandro Armuzzi, MD
ECCO 2023
Comprehensive overview of surgery in IBD
Massimo Claudio Fantini, MD
ECCO 2023
New opportunities from the application of artificial intelligence (AI) to the new endoscopic technologies
ECCO 2023
Massimo Claudio Fantini, MD
Nuove opportunità dall’applicazione dell’intelligenza...
Iris Dotan, MD
ECCO 2023
Mucosal signatures suggest a mechanism for early CD postoperative recurrence
Fernando Gomollón, MD
ECCO 2023
Una vida mejor en el futuro inmediato para nuestros pacientes
Alessandro Armuzzi, MD
ECCO 2023
Sequencing nelle malattie infiammatorie cronicale intestinali
Piotr Eder, MD
ECCO 2023
Nowe wytyczne ECCO dotyczące manifestacji pozajelitowych w IBD
Alessandro Armuzzi, MD
ECCO 2023
Panoramica completa sulla chirurgia nelle malattie infiammatorie cronicale intestinali
Massimo Claudio Fantini, MD
ECCO 2023
Nuove opportunità dall’applicazione dell’intelligenza artificiale alle nuove tecniche endoscopiche
Do you need a login? team@onkowissen.de
Durch die Eingabe Ihrer individuellen einheitlichen Fortbildungsnummer (EFN) können Sie CME Fortbildungspunkte sammeln. Die bayrische Landesärztekammer erkennt dabei in jedem Fortbildungsmodul pro 45 min Videoeinheit 2 CME Punkte an. Maximal sind pro Fortbildungsmodul 4 CME Punkte möglich. Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Die Fortbildungseinheiten verteilen sich auf folgende Fortbildungsmodule:
Durch die Eingabe Ihrer individuellen einheitlichen Fortbildungsnummer (EFN) können Sie CME Fortbildungspunkte sammeln. Die bayrische Landesärztekammer erkennt dabei in jedem Fortbildungsmodul pro 45 min Videoeinheit 2 CME Punkte an. Maximal sind pro Fortbildungsmodul 4 CME Punkte möglich. Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Die Fortbildungseinheiten verteilen sich auf folgende Fortbildungsmodule: